. Author manuscript; available in PMC: 2017 Jan 3.

Published in final edited form as: Biochem Biophys Res Commun. 2016 Jul 25;478(2):559–564. doi: 10.1016/j.bbrc.2016.07.100

Table 2.

Metabolism of ¹²⁵I-Ang-(1-12) and ¹²⁵I-Ang I by chymase and ACE enzymes in SHR heart and lung (PMs).

Tissue/Substrate	Chymase activity	ACE activity
Heart (PMs)
¹²⁵I-Ang-(1-12) substrate	7.0 ± 0.6^a,^b	1.8 ± 0.2^c,^d
¹²⁵I-Ang I substrate	0.8 ± 0.1^b	1.8 ± 0.3
Lungs (PMs)
¹²⁵I-Ang-(1-12) substrate	33 ± 1.2^a,^b	239 ± 25^c,^d
¹²⁵I-Ang I substrate	2.1 ± 0.1^b	248 ± 34

Chymase and ACE mediated generation of ¹²⁵I-Ang II product from the metabolism of either ¹²⁵I-rAng-(1-12) or ¹²⁵I-Ang I substrate (1 nmol/L) were analyzed in SHR rat heart and lung native and soluble PMs preparations as described in the Methods. The contribution of chymase and ACE activity (fmol Ang II formation/min/mg) was calculated based on ¹²⁵I-Ang II product analysis by HPLC in each sample incubated with or without specific chymase or ACE inhibitor as described in Table 1. Data are expressed as mean ± SEM. Each experiment was done at least three times.

Significantly different (P < 0.001) vs. corresponding ¹²⁵I-Ang I substrate.

Significantly different (P < 0.001) vs. corresponding ACE activity.

NS = Not significantly different vs. corresponding ¹²⁵I-Ang I substrate

NS = Not significantly different vs. corresponding ACE activity.